Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Gregory J. Gores(Mayo Clinic in Arizona), Adrian M. Di Bisceglie(Saint Louis University), Michael T. Lotze(University of Pittsburgh), Morris Sherman(University Health Network), Myron Schwartz(Icahn School of Medicine at Mount Sinai), Riccardo Lencioni(University of Pisa), Jordi Bruix(Hospital Clínic de Barcelona), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Barnett S. Kramer(University of Pittsburgh), Jayant A. Talwalkar(Mayo Clinic)
Cited by 1,663
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.4k